File downloaded on 2026-11-01
Source URL: https://medicines.health.europa.eu/veterinary/en/600000053625

Calcibel Forte, 380/60/50 mg/ml solution for infusion for horses, cattle, sheep, goats and pigs

Authorised

- Calcium gluconate
- Magnesium chloride hexahydrate
- Boric acid

Product identification

Medicine name:
Calcibel Forte, 380/60/50 mg/ml solution for infusion for horses, cattle, sheep, goats and pigs

Active substance:
Calcium gluconate
Magnesium chloride hexahydrate
Boric acid

Target species:
Horse
Cattle
Sheep
Goat
Pig

Route of administration:
Intravenous use

Product details

Active substance and strength:

Calcium gluconate
380.00 milligram(s) / 1.00 millilitre(s)

Magnesium chloride hexahydrate
60.00 milligram(s) / 1.00 millilitre(s)

Boric acid
50.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for infusion

Withdrawal period by route of administration:

Intravenous use:

- **Horse**
  - Milk. 0 hour
  - Meat and offal. 0 day
- **Cattle**
  - Milk. 0 hour
  - Meat and offal. 0 day
- **Sheep**
  - Milk. 0 hour
  - Meat and offal. 0 day
- **Goat**
  - Milk. 0 hour
  - Meat and offal. 0 day

- **Pig**
  - Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QA12AX

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Greece

Available in:
Greece

Package description:
Plastic Bottle 12 x 500.0 millilitre(s)
Plastic Bottle 1 x 500.0 millilitre(s)

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Bela-Pharm GmbH & Co. KG

Marketing authorisation date:
20/09/2021

Manufacturing sites for batch release:

Bela-Pharm GmbH & Co. KG

Responsible authority:
National Organization For Medicines

Authorisation number:
84808/21-09-2021/K-0214302

Date of authorisation status change:
20/09/2021

Reference member state:
Czechia

Procedure number:
CZ/V/0170/001

Concerned member states:
Austria Cyprus Denmark Estonia Finland Greece Hungary Iceland Ireland Italy Latvia Lithuania Poland Portugal Romania Slovakia Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 14/03/2026
Download

Package Leaflet

English (PDF)
Published on: 14/03/2026
Download

Labelling